CCR5 and cancer: Also, the use of drugs with double anticancer/anti-inflammatory action such as acalabrutinib (a Bruton’s tyrosine kinase inhibitor) or leronlimab (an antibody against CCR5 with anti-metastatic activity) is currently being evaluated in the COVID-19 setting (Table 1) and in the future may find an increased use the treatment of cancer patients with COVID-19.